HRP20080686T3 - Method of purifying pravastatin - Google Patents

Method of purifying pravastatin

Info

Publication number
HRP20080686T3
HRP20080686T3 HR20080686T HRP20080686T HRP20080686T3 HR P20080686 T3 HRP20080686 T3 HR P20080686T3 HR 20080686 T HR20080686 T HR 20080686T HR P20080686 T HRP20080686 T HR P20080686T HR P20080686 T3 HRP20080686 T3 HR P20080686T3
Authority
HR
Croatia
Prior art keywords
methyl
pravastatin
compactin
hydroxy
containing less
Prior art date
Application number
HR20080686T
Other languages
English (en)
Croatian (hr)
Inventor
Keri Vilmos
Melczer Istvan
Original Assignee
Teva Gy�gyszergy�r Z�rtk�r�en M�k�d� R�szv�nyt�rsas�g
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Gy�gyszergy�r Z�rtk�r�en M�k�d� R�szv�nyt�rsas�g filed Critical Teva Gy�gyszergy�r Z�rtk�r�en M�k�d� R�szv�nyt�rsas�g
Publication of HRP20080686T3 publication Critical patent/HRP20080686T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
HR20080686T 2003-11-24 2004-11-23 Method of purifying pravastatin HRP20080686T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52549403P 2003-11-24 2003-11-24
US53231403P 2003-12-22 2003-12-22
US55416504P 2004-03-18 2004-03-18
PCT/US2004/039217 WO2005051372A2 (en) 2003-11-24 2004-11-23 Method of purifying pravastatin

Publications (1)

Publication Number Publication Date
HRP20080686T3 true HRP20080686T3 (en) 2009-03-31

Family

ID=34637188

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080686T HRP20080686T3 (en) 2003-11-24 2004-11-23 Method of purifying pravastatin

Country Status (12)

Country Link
US (2) US7425644B2 (de)
EP (2) EP1641447B1 (de)
JP (2) JP2007512366A (de)
AT (1) ATE412409T1 (de)
CA (1) CA2546377A1 (de)
DE (3) DE202004020671U1 (de)
ES (1) ES2251894T3 (de)
HR (1) HRP20080686T3 (de)
PL (1) PL1641447T3 (de)
PT (1) PT1641447E (de)
TW (1) TWI319707B (de)
WO (1) WO2005051372A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121062A2 (en) * 2004-06-09 2005-12-22 Ranbaxy Laboratories Limited Process for the preparation of pravastatin
JP4775727B1 (ja) * 2010-08-17 2011-09-21 貞宏 平山 印刷物の微小マークによる一般人が容易にできる真贋判定方法
WO2014119568A1 (ja) * 2013-01-29 2014-08-07 学校法人産業医科大学 シスプラチン耐性がんの治療のためのHMG-CoA還元酵素阻害薬の使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4346277A (en) * 1979-10-29 1982-08-24 Eaton Corporation Packaged electrical heating element
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
DE3682557D1 (de) 1985-09-13 1992-01-02 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US4857547A (en) 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857522A (en) 1988-03-21 1989-08-15 E. R. Squibb & Sons, Inc. Derivatives of pravastatin for inhibiting cholesterol biosynthesis
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5099035A (en) 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5202029A (en) 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
US5157025A (en) 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
RU2116312C1 (ru) 1992-05-20 1998-07-27 Басф Акциенгезельшафт Производные пептида или их соли, фармацевтическая композиция
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
IL112639A0 (en) 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5942423A (en) 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
ATE189804T1 (de) 1995-08-03 2000-03-15 Dsm Nv Selektives verfahren zur deacylierung von acylverbindungen
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
WO1998037220A1 (en) 1997-02-20 1998-08-27 Dsm N.V. Nitrogen feed in statin fermentation
KR100210482B1 (ko) 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
AU9264598A (en) 1997-08-22 1999-03-16 Gist-Brocades B.V. Statin production by fermentation
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
JP2931971B1 (ja) 1998-02-23 1999-08-09 利夫 佐藤 プラバスタチンの製造法
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SK10932001A3 (sk) 1999-02-03 2002-06-04 Institute For Drug Research Ltd. Mikrobiálny spôsob výroby pravastatínu
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
JP3881240B2 (ja) 1999-11-30 2007-02-14 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 醗酵ブロスからスタチン化合物を回収するための方法
AU2000255633A1 (en) 2000-04-27 2001-11-07 Biocon India Limited A novel process for the manufacture and purification of compactin
CN1468098A (zh) * 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物
JP3463881B2 (ja) * 2002-08-06 2003-11-05 三共株式会社 プラバスタチン又はその薬理上許容される塩の単離・精製方法
TW589178B (en) * 2003-02-21 2004-06-01 China Chemical & Pharmaceutica A novel industrial process to obtain pravastatin sodium of high purity

Also Published As

Publication number Publication date
ATE412409T1 (de) 2008-11-15
EP1641447A2 (de) 2006-04-05
EP1641447B1 (de) 2008-10-29
US7425644B2 (en) 2008-09-16
ES2251894T3 (es) 2009-04-01
CA2546377A1 (en) 2005-06-09
DE602004017461D1 (de) 2008-12-11
PT1641447E (pt) 2008-12-10
EP2033636A1 (de) 2009-03-11
TWI319707B (en) 2010-01-21
DE202004020671U1 (de) 2005-12-08
WO2005051372A2 (en) 2005-06-09
DE04811862T1 (de) 2006-03-02
JP2007512366A (ja) 2007-05-17
TW200518745A (en) 2005-06-16
JP2009161542A (ja) 2009-07-23
US20080300305A1 (en) 2008-12-04
PL1641447T3 (pl) 2009-04-30
ES2251894T1 (es) 2006-05-16
US20050113446A1 (en) 2005-05-26
WO2005051372A3 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
ATE380020T1 (de) Stabile arzneiformulierungen enthaltend pravastatin or atorvastatin
IL187261A0 (en) Crystals of the sodium salt of pravastatin
EP1466886A3 (de) Neue Salze von HMG-CoA Reductase-inhibitoren
WO2002036534A3 (en) Processes for preparing linear polyglycerols and polyglycerol esters
ATE260101T1 (de) Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
PE20020340A1 (es) Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos
CO4810331A1 (es) Proceso para la preparacion de esteres en presencia de un catalizador
CA2324283A1 (en) Pharmaceutical composition containing a statin and aspirin
AU2001285765A1 (en) Medium chain fatty acids applicable as antimicrobial agents
AU2003285546A1 (en) Catalyst and process
IS5886A (is) Aðferð til að öðlast mjög hreina HMG-CoA redúktasahemla
WO2003082799A3 (de) Alicyclische ester mit moschusgeruch
HRP20080686T3 (en) Method of purifying pravastatin
AR080023A1 (es) Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa
WO2003059249A3 (en) Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same
WO2001044144A3 (en) Process for the preparation of sodium salts of statins
AU2003272077A1 (en) Alpha-amino acid benzothiazolylthio ester as intermediates for manufacture of ace inhibitors and process for preparation thereof
CO5611117A2 (es) Combinacion de compuestos organicos
US20040048805A1 (en) Antilipemic agents
HK1084661A (zh) 药学组合物的羧酸酯
AU2001289428A1 (en) Oral pharmaceutical composition containing a combination of fenofibrate and a hmg-coa reductase inhibitor
HUP0202173A2 (en) Hydroxylation of compactin to pravastatin by micromonospora